MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

2.980 -0.100 (-3.25%)
Streaming Delayed Price Updated: 9:43 AM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
TEVA Stock Pops 4% as Teva Receives FDA Approval ↗
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar. 
Via InvestorPlace
News headline image
Why Is Altimmune (ALT) Stock Up 14% Today? ↗
Altimmune stock is rising higher on Monday as ALT investors react to positive news from rival weight loss drugmaker Zealand Pharma. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
(ALT) - Analyzing Altimmune's Short Interest ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Altimmune? ↗
 
Via Benzinga
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
News headline image
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - February 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of... 
Via TheNewswire.com
News headline image
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report ↗
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble. 
Via InvestorPlace
News headline image
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End' ↗
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position 
Via Benzinga
News headline image
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. 
Via Benzinga
News headline image
Jim Cramer Calls Affirm 'A Winner,' But Not C3.ai: 'I Can't Recommend A Stock With No Earnings' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vertiv Holdings Co (NYSE: VRT) is "one of the great per 
Via Benzinga
News headline image
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs ↗
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments. 
Via InvestorPlace
News headline image
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
News headline image
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy in January 2024 ↗
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. 
Via InvestorPlace
News headline image
Harpoon Therapeutics, Heron Therapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 150 points on Monday. Shares of Harpoon Therapeutics, Inc.(NASDAQ: HARP) rose sharply in pre-market trading.... 
Via Benzinga
Topics Stocks
News headline image
What's Going On With Obesity Drug-Developer Altimmune Inc Stock? ↗
Altimmune, Inc. (NASDAQ: ALT) shares are trading higher Thursday, and the stock has gained more than 140% over the past month. 
Via Benzinga
News headline image
Weight Watchers gains from Oprah’s GLP-1 weight-loss
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
News headline image
Coherus BioSciences And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures were slightly lower this morning, with the Dow Jones futures falling around 5 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December ↗
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &... 
Via Benzinga
Topics ETFs
News headline image
MarketBeat Week in Review: 12/11 - 12/15
The rally in stocks moved into high gear on hopes for interest rate hikes next year; conditions are right for the rally to continue into 2024. 
Via MarketBeat
Topics Economy
News headline image
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
News headline image
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them' ↗
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs. 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story